Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming ...

The company has a market cap of $548.51 million, a PE ratio of -51.92 and a beta of 1.98. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78 ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq ...

The positive CHMP opinion is supported by positive six-month adolescent Phase 3 data which Valneva reported in May 2024 2. These data, collected through a study in Brazil funded by the Coalition ...

Saint-Herblain (France), March 3, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor ...

Ratings for Valneva VALN were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Valneva Trading Down 5.9 % Valneva stock opened at $7.44 on Friday. The stock has a market cap of $604.57 million, a PE ratio of -57.23 and a beta of 1.98. Valneva has a 52 week low of $3.62 and a ...

Investing.com -- El fabricante francés de vacunas Valneva ha anunciado sus expectativas de un aumento en las ventas y un flujo de caja positivo para el año 2025. Se prevé que los ingresos ...

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business ...